Physician profile
Ryan Kelm
NPI 1043772627
$2,389.14
in general payments reported to CMS, 2019-2025
14 companies · $99.51 in 2025
The $99.51 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $27.74 · 2021: $424 · 2022: $1,113 · 2023: $499 · 2024: $226 · 2025: $99.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $819 · Education: $5.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $819.10 |
| Education | $5.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $783.91 | 2020-2024 | |
| Galderma Laboratories, L.P. | $256.81 | 2021-2023 | |
| Janssen Biotech, INC. | $220.45 | 2021-2024 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $167.64 | 2022 | |
| Vyne Pharmaceuticals INC. | $147.16 | 2021 | |
| Lilly USA, LLC | $134.41 | 2022 | |
| Genzyme Corporation | $132.01 | 2022-2023 | |
| Stemline Therapeutics INC. | $122.11 | 2023 | Orserdu |
| Pfizer INC. | $110.35 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $109.50 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $99.51 | 2025 | |
| Sanofi-Aventis U.S. LLC | $64.95 | 2022 | |
| Ucb, INC. | $24.40 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $15.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Kelm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.